Celgene Announces 2012 Financial Outlook, Reviews 2011; Apricus and Abbott Sign Exclusive Agreement to Market Vitaros in Canada Print E-mail
By Staff and Wire Reports   
Monday, 09 January 2012 20:22
Below is a look at some of the headlines for companies that made news in the healthcare sector on January 9, 2012.

Celgene Corporation (NASDAQ:CELG) reviewed 2011 achievements and provided its outlook for 2012 at the JPMorgan 30th Annual Healthcare Conference.

In 2012, non-GAAP total revenue is targeted to increase approximately 15 percent year-over-year to a range of $5.4 to $5.6 billion. REVLIMID net product sales are expected to increase approximately 19 percent to a range of $3.75 to $3.85 billion. Non-GAAP diluted earnings per share (EPS) is targeted to increase approximately 25 percent to a range of $4.70 to $4.80. The EPS guidance assumes a constant share count from 2011 to 2012.

The 2012 guidance reflects our confidence in the continued operational momentum in executing our business plan by our global teams, said Bob Hugin, Celgenes Chairman and Chief Executive Officer. The accomplishments of 2011 have positioned us with significant catalysts for 2012 in all three therapeutic areas of our business hematology, oncology, and inflammation and immunology.

Preliminary 2011 unaudited results indicate that non-GAAP total revenue increased by approximately 34 percent to just over $4.8 billion. Non-GAAP diluted EPS increased approximately 36 percent to about $3.79. The Company will report its 2011 full-year financial results on Thursday, January 26, 2012.


Apricus Biosciences, Inc. (Nasdaq:APRI)
announced it has entered into an exclusive licensing agreement granting Abbott Laboratories Limited (NYSE:ABT) the exclusive rights to market Vitaros® (alprostadil), Apricus Bio's treatment for erectile dysfunction, in Canada. "We are optimistic about the potential of the technology, effectiveness and market potential of Vitaros®," said Dr. Bassam Damaj, Chairman, President and Chief Executive Officer of Apricus Bio.

Under the terms of agreement, Abbott will commercialize and market Vitaros® in Canada where the drug was approved by Health Canada in late 2010, with launch anticipated in 2012. Over the lifetime of the deal, Apricus Bio will receive up to approximately $16 million in up-front, regulatory and sales milestone payments, plus tiered royalty payments based on Abbott's sales of the product in Canada.

Also Monday:

("3SBio" or "the Company"), a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced Mr. Bo Tan, 3SBio's chief financial officer will attend the UBS Greater China Conference 2012 in Shanghai on January 11, 2012.

Acorda Therapeutics, Inc. (Nasdaq: ACOR)
today announced that AMPYRA® (dalfampridine) Extended Release Tablets, 10 mg unaudited net sales for the fourth quarter of 2011 were $57 million and unaudited AMPYRA 2011 full year net sales were $210 million.

Adherex Technologies Inc. (TSX:AHX) (PINKSHEETS:ADHXF)
, a biopharmaceutical company focused on the development of Eniluracil plus 5-Fluorouracil (5-FU) and Leucovorin, announced fifty percent (70/140) of the patients have been enrolled in the company's on-going Phase 2 clinical trial for Metastatic Breast Cancer.

Agilent Technologies Inc. (NYSE:A)
today announced the launch of the Agilent 8800 triple quadrupole ICP-MS (ICP-QQQ), the first and only instrument of its kind.

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY)
, a leading RNAi therapeutics company, announced today its key “Alnylam 5x15” and partner program goals for 2012.

AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG)
today announced a business update, including preliminary fourth quarter 2011 financial results and its outlook for 2012. The company will present further details at the 30th Annual J.P. Morgan Healthcare Conference in San Francisco on January 11, 2012 at 3:00 p.m. Pacific time.

AxoGen, Inc. (OTCBB: AXGN)
today announced that it will be presenting at the Eighth Annual Noble Financial Equity Conference at the Hard Rock Hotel in Hollywood, Florida.

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)
today announced long-term results from the extension phase of its randomized Phase 2b study of BCX4208 added to allopurinol in patients with gout who had failed to reach the serum uric acid (sUA) therapeutic goal of <6 mg/dL on allopurinol alone.

BioReliance, a leading provider of global biopharmaceutical testing services, announced today that it has agreed to be acquired by Sigma-Aldrich Corporation (NASDAQ: SIAL).

Celgene Corporation (NASDAQ: CELG)
today reviewed 2011 achievements and provided its outlook for 2012 at the JPMorgan 30th Annual Healthcare Conference.

diaDexus, Inc. (OTC Bulletin Board: DDXS.OB)
, a diagnostics company focused on patent-protected in vitro diagnostic products addressing unmet needs in cardiovascular disease, today announced preliminary Q4 2011 revenues of approximately $4.9 million, up 48% from the prior year's fourth quarter.

Emergent BioSolutions Inc. (NYSE: EBS)
today announced preliminary 2011 financial results and provided guidance for 2012.

Chembio Diagnostics, Inc. (OTC.PK: CEMI and OTC.QB: CEMI)
, which develops, manufactures, markets and licenses point-of-care diagnostic tests, today announced that Lawrence A. Siebert, President and Chief Executive Officer, will present at the Biotech Showcase in San Francisco at approximately 5:30 pm Eastern Time (2:30 pm Pacific Time) on Wednesday, January 11, 2012.

Hologic, Inc. (Hologic or the Company) (NASDAQ: HOLX), a leading developer, manufacturer and supplier of premium diagnostics products, medical imaging systems and surgical products dedicated to serving the healthcare needs of women, today announced that Conceptus, Inc.'s (Conceptus) request for an injunction barring future sales of Hologic's Adiana permanent contraception (Adiana) system has been denied and that no royalty will be due to Conceptus on such sales.

Human Genome Sciences, Inc. (Nasdaq: HGSI) will today announce its priority goals for 2012 and report on progress with the commercialization of BENLYSTA® (belimumab), the first approved drug for systemic lupus in 56 years, during a presentation this afternoon by H. Thomas Watkins, President and Chief Executive Officer, to financial analysts and investors at the 30th Annual JPMorgan Healthcare Conference in San Francisco.

ICON plc, (NASDAQ: ICLR),a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced that is has signed a strategic partnership with Shire Specialty Pharmaceuticals to serve as the sole global provider of central laboratory services and one of two strategic partners for clinical development services.

Idenix Pharmaceuticals, Inc. (NASDAQ: IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced interim data from a 12-week phase IIb clinical trial of IDX184, the Company's lead product candidate for the treatment of hepatitis C virus (HCV) infection.

Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) today announced that Merck, known as MSD outside the United States and Canada, has selected several novel Toll-like Receptor (TLR) agonists targeted to TLR7, TLR8 or TLR9 for evaluation and use as vaccine adjuvant candidates under the companies' collaboration and license agreement.

Interleukin Genetics, Inc. (OTCQB: ILIU) announced today that CEO Lewis H. Bender will present at the Biotech Showcase™ 2012 at the Wyndham Parc 55 Hotel, 55 Cyril Magnin Street in San Francisco.

Lixte Biotechnology Holdings (OTC: LIXT.PK) announces that the United States Patent and Trademark Office awarded a patent for the use of lead compounds from each of two different types of drugs, protein phosphatase inhibitors and histone deacetylase inhibitors, for the potential prevention and treatment of neurodegenerative diseases.

Blogs from Bob Lorsch, CEO of MMRGlobal, Inc. (OTCBB: MMRF), are available at http://blog.mmrglobal.com.

Navidea Biopharmaceuticals (NYSE Amex: NAVB) today announced that Thomas Tulip, Executive Vice President and Chief Business Officer of Navidea, will participate with five other biopharmaceutical executives as an expert panelist in a workshop entitled, Molecular Diagnostics: A Sector of Increasing Importance on Wednesday, January 11, 2012 from 8:00 AM – 9:00 AM PT at the Biotech Showcase Conference in San Francisco.

Neuralstem, Inc. (NYSE Amex: CUR) announces that President and CEO Richard Garr will present at the 2012 Biotech Showcase in San Francisco on Tuesday, January 10, 1:45-3:00pm PT. Garr will serve on the Therapeutic Focus Panel entitled, "Neurodegenerative Disease, Ophthalmology and Spinal Injury," featured in the Alliance for Regenerative Medicine (ARM) Insight Track.

NHS Health Solutions, Inc. (PINKSHEETS: NHSH) is pleased to announce that its wholly owned subsidiary Mineseeker Operations Overseas Limited ("Mineseeker" or "Company"), a British Virgin Islands corporation, has made significant advancements toward its target to be under revenue by the second quarter of 2012.

Northwest Biotherapeutics (OTC.BB: NWBO) (NW Bio) today announced that it successfully met its projection that it would have 25 trial sites open and recruiting by the end of Q4, 2011, in its ongoing clinical trial of DCVax®immune therapy for Glioblastoma multiforme (GBM), the most lethal form of brain cancer.

Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today provided updated timing for its commercial launch of EXPAREL® (bupivacaine liposome injectable suspension), a non-opioid analgesic that was approved by the U.S. Food and Drug Administration (FDA) for administration into the surgical site to produce postsurgical analgesia.

PAREXEL International Corporation (NASDAQ: PRXL)
announced today that it will be presenting at the J. P. Morgan Healthcare Conference in San Francisco at 2:30 p.m. PT on Wednesday, January 11, 2012.

Polycom, Inc. (NASDAQ: PLCM)
, the global leader in standards-based unified communications (UC), today launched the Polycom® SpectraLink® 8452, the first enterprise-grade Voice-Over Wi-Fi handset with an integrated 2D barcode scanner.

Houston, Texas, the home base of Rainbow Coral Corp.’s (OTCBB:RBCC) biosciences division, is bursting with potential customers for n3D’s Bio-Assembler system.

SpectraScience, Inc. (OTCQB: SCIE) (PINKSHEETS: SCIE), a San Diego based medical device company, today announced that President and Chief Executive Officer Michael Oliver will present to investors and analysts at the OneMedForum in San Francisco at the Sir Francis Drake Hotel.

Transgenomic, Inc. (OTCBB: TBIO) and Power3 Medical Products, Inc. (OTCBB: PWRM) today announced that, following mediation through the offices of the United States District Court for the District of Nebraska, all pre-existing litigations and disputes between the companies have been resolved and terminated, effective immediately.

Unigene Laboratories, Inc. (OTCBB: UGNE) today provided a business outlook for 2012 and highlighted multiple near-term catalysts that have the potential to monetize assets and unlock significant value over the next 12 months.

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) today announced its 2012 business objectives in conjunction with the 30th Annual J.P. Morgan Healthcare Conference in San Francisco.

VIVUS, Inc. (NASDAQ: VVUS) today announced that following recent discussions with Food and Drug Administration (FDA) officials, the company has been asked to remove the Qnexa® contraindication for women of childbearing potential contained in the proposed label.  Qnexa would remain contraindicated for women who are pregnant.

WuXi PharmaTech (NYSE: WX), a leading pharmaceutical, biotechnology, and medical-device research and development outsourcing company, with operations in China and the United States, today announced that it will present at the 30th Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2012 at 4:30 p.m. Pacific Standard Time and updated its 2011 financial guidance.

"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus